NICKY PANIAGUA: Open Payments
NPI 1306665658 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 13 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $731
Food & beverage: $731
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $297 |
| GlaxoSmithKline, LLC. | 1 | $123 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $114 |
| Kowa Pharmaceuticals America, Inc. | 1 | $102 |
| Astellas Pharma US Inc | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: QULIPTA, VRAYLAR, AREXVY, CAPLYTA, ZORYVE, Veozah, BREZTRI, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
